Topical Immunomodulation in Dermatology
- 1 August 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 30 (8) , 1101-1112
Abstract
BACKGROUND Topical immunomodulators include both immunostimulatory and immunosuppressive agents. If successful, topical immunotherapy may represent an important improvement in the therapy of inflammatory dermatoses, viral infections, and cancers of the skin and genital mucosa. Topical immunotherapy using obligate contact sensitizers such as diphencyprone or dinitrochlorobenzene has been used against viral (e.g., common warts) and autoimmune diseases (e.g., alopecia areata). RESULTS Newer agents such imidazoquinolines (imiquimod and resiquimod) act by cytokine secretion from monocytes/macrophages (interferon-α, interleukin-12, tumor-necrosis factor-α). The locally generated immune milieu leads to a Th1-dominance and cell-mediated immunity that have been clinically used to treat viral infections such as human papillomavirus, herpes simplex virus, and mollusca. Although these agents improve antigen presentation by dendritic cells, they also act on B cells leading to the synthesis of antibodies such as IgG2a. We have also introduced this treatment against cancerous lesions including initial squamous cell and basal cell carcinoma in immunocompetent and immunosuppressed patients. We provide examples of successful treatment of squamous cell cancer using topical imiquimod. CONCLUSION The available and additional Toll-like receptor agonists will help to improve the specific dermatologic therapy. Topical immunotherapy with both immunostimulatory and immunosuppressive agents bears potential for effective and patient friendly treatment of inflammatory, infectious, and cancerous skin diseases. Long-term evaluation will define the tolerability and safety profile of these novel topical agents.Keywords
This publication has 90 references indexed in Scilit:
- Inhibition of IgE Production by the Imidazoquinoline Resiquimod in Nonallergic and Allergic DonorsJournal of Investigative Dermatology, 2002
- Adjuvant Activities of Immune Response Modifier R-848: Comparison with CpG ODNCellular Immunology, 2000
- The Imidazoquinolines, Imiquimod and R-848, Induce Functional, but Not Phenotypic, Maturation of Human Epidermal Langerhans' CellsClinical Immunology, 2000
- CpG DNA rescues B cells from apoptosis by activating NFκB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathwayInternational Immunology, 1999
- Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% creamJournal of the American Academy of Dermatology, 1999
- Immunomodulating and antiviral activities of the imidazoquinoline S-28463Antiviral Research, 1995
- Contact immunotherapy of resistant wartsJournal of the American Academy of Dermatology, 1988
- Dinitrochlorobenzene immunotherapy for verrucae resistant to standard treatment modalitiesJournal of the American Academy of Dermatology, 1982
- TOPICAL DNCB THERAPY FOR RESISTANT WARTSAustralasian Journal of Dermatology, 1978
- Experiences with local chemotherapy and immunotherapy in premalignant and malignant skin lesionsCancer, 1970